The ability of the 5D3/CP33 engager to mediate targeted elimination of PSMA-positive cancer cells at particularly low concentrations would be beneficial in vivo, where lower dosage can minimize adverse immunogenic effects such as the anti-drug antibody (ADA) response or the cytokine release syndrome [80,81]. Here, FOLH1 is linked to cancer.